The StarBright Blue 700, StarBright Violet 440 and StarBright Violet 610 Dyes offer maximal brightness for improved resolution

HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today launched three StarBright Dyes specifically developed for flow cytometry.

StarBright Blue 700, StarBright Violet 440, and StarBright Violet 610 are fluorescent nanoparticles that are conjugated to Bio-Rad’s highly validated flow antibodies, providing maximal brightness and improved resolution. Brighter than other fluorescent dyes with similar excitation and emission spectra, the StarBright dyes provide researchers with an alternative for flow cytometry panels. The brightness of the dyes combined with precise excitation and emission profiles offer improved resolution of rare populations and low-density antigens and easily integrate into multiplex panels.

“StarBright Dyes offer exceptional brightness with specific excitation and emission, allowing researchers to build brighter flow cytometry panels to enable better resolution of positive populations from background without the need for special buffers,” said Mike Blundell, Bio-Rad Product Manager, Life Science Group. “The unique profile of these dyes combined with Bio-Rad’s high-quality antibodies provides flexibility and offers a reliable alternative for incorporation into flow cytometry protocols.”

Key Benefits of StarBright Dyes

• Resistant to photobleaching and highly stable with minimal lot-to-lot variation, enabling researchers to achieve consistent and reproducible staining
• Work with all common staining buffers, including special polymer dye staining buffers, for easy integration into multicolor panels
• The unique chemistry ensures no loss of signal in fixation
• Offer narrow excitation and emission profiles for improved resolution in new and existing flow cytometry experiments

StarBright Dyes are compatible with Bio-Rad’s ZE5 Cell Analyzer, S3e Cell Sorter, as well as other conventional and spectral flow cytometers.

For more information about StarBright Blue 700, StarBright Violet 440 and StarBright Violet 610 Dyes, please visit: www.bio-rad-antibodies.com/starbright 

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.